Cholestatic Liver Disease Clinical Trials

18 clinical trials for Cholestatic Liver Disease across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Vitamin D2 vs Vitamin D2 Plus Calcitriol in Cholestatic Children With Vitamin D Deficiency — RECRUITING · PHASE4
• Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease — RECRUITING · PHASE1
• Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease — RECRUITING · PHASE1
• DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE — RECRUITING · NA
• Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis — RECRUITING
• Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers — RECRUITING
• Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). — COMPLETED · PHASE2
• A PHASE 1 TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PK, AND PD of AX-0810 IN HEALTHY PARTICIPANTS — TERMINATED · PHASE1
• MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study — COMPLETED · PHASE2
• Application and Effect Evaluation of Medium Chain Fatty Acid Rich Milk Powder in Infants With Cholestatic Liver Disease — WITHDRAWN · NA
• Probiotics in Pediatric Chronic Cholestasis — OTHER · PHASE2
• A LONG-TERM SAFETY STUDY OF MARALIXIBAT, AN APICAL SODIUM DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN SUBJECTS WHO PREVIOUSLY PARTICIPATED IN A MARALIXIBAT STUDY — COMPLETED
• Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC — COMPLETED · PHASE3
• A MULTICENTRE EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC SUBJECTS WITH ALAGILLE SYNDROME — COMPLETED
• THE EVALUATION OF THE INTESTINAL BILE ACID TRANSPORT (IBAT) INHIBITOR LUM001 IN THE REDUCTION OF PRURITUS IN ALAGILLE SYNDROME, A CHOLESTATIC LIVER DISEASE — COMPLETED
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PAEDIATRIC PATIENTS WITH ALAGILLE SYNDROME — COMPLETED
• OPEN LABEL STUDY OF THE EFFICACY AND LONG TERM SAFETY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATMENT OF CHOLESTATIC LIVER DISEASE IN PEDIATRIC PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS — COMPLETED

Refine this search